RxDoctor Payments Data

Kevin Kapadia, MD

Neurology · Santa Barbara, CANPI 1255565875

Payments from drug & device makers

$11,163in general payments, 2019–2025

Across 545 payments — averaging $20.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Pfizer$670
  • UCB, Inc.$635
  • Biogen$538
  • Novartis$505
  • Sanofi$368
  • plus $5K from 46 others

What the payments were for

  • Food & beverage$11,06999%
  • Education$941%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,163 in reported general payments places this provider in the 70th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$284,359
Medicare patients
616
Services billed
13,778

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5013$264,780
Nurtec OdtRimegepant Sulfate68$110,246
Aimovig AutoinjectorErenumab-Aooe39$30,559
UbrelvyUbrogepant20$19,388
Emgality PenGalcanezumab-Gnlm22$17,441
Carbidopa-LevodopaCarbidopa/Levodopa238$9,205
Memantine Hcl204$7,809
Topiramate ErTopiramate13$6,965
Carbidopa-Levodopa ErCarbidopa/Levodopa116$4,717
Gabapentin251$3,473
Donepezil Hcl218$3,143
Memantine Hcl ErMemantine Hcl20$2,730
Propranolol Hcl ErPropranolol Hcl87$2,638
Pregabalin94$2,599
Duloxetine Hcl67$1,867

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$670$110,24668 claims
AbbVieUbrelvy$3,441$19,38820 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$140$1,66114 claims
Upsher-smith Laboratories LLCTopiramate$15$35622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,996 neurology providers in California.

Other neurology in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →